Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD). RESEARCH DESIGN AND METHODS: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin. MAIN OUTCOME MEASURES: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode real-time ultrasound were assessed at baseline and 4 and 8 months. RESULTS: Glycated hemoglobin reduced significantly in both groups. No significant changes were found in body weight, waist circumference and lipids. Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473). CONCLUSION: Eight months of liraglutide use in patients with T2DM and NAFLD significantly reduced carotid IMT, a surrogate marker of atherosclerosis, independently of glucometabolic changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“It also improves hypertension, dyslipidemia and vascular endothelial dysfunction, thus leading to a lower overall cardiovascular disease (CVD) risk [3-6].”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 1×
“It is noteworthy that although GLP-1 receptors exist in human hepatocytes [24,25], the mechanism of action of GLP-1 receptor agonists in NAFLD is incompletely understood.”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“It is noteworthy that although GLP-1 receptors exist in human hepatocytes [24,25], the mechanism of action of GLP-1 receptor agonists in NAFLD is incompletely understood.”
BackgroundArmstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · cited 4×
“Several studies showed a reduction of the glycemic parameters in diabetic patient with NAFLD after liraglutide therapy [11,12], suggesting that its action on glycemic control and body weight (at a dose of 1.”
BackgroundResultInfluentialHogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · cited 4×
“Several studies showed a reduction of the glycemic parameters in diabetic patient with NAFLD after liraglutide therapy [11,12], suggesting that its action on glycemic control and body weight (at a dose of 1.”
BackgroundInfluentialKotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196 · cited 1×
“The high prevalence of NAFLD in patients with T2DM and its association with increased CVD risk is well documented [22,23].”
BackgroundGlucagon-like peptide-1 analogues: An overview
Gupta, V. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111625 · Cited by 186 · cited 1×
“Liraglutide is a long-acting, acylated glucagon-like peptide-1 (GLP-1) analogue, which acts as a strong agonist on the GLP-1 receptor and is widely used in the treatment of type 2 diabetes mellitus (T2DM) [1].”
BackgroundOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Cited by
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Self-citationGlucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Tian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80
Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18
“In general, whether the vasculoprotective action of GLP1-RAs is mainly attributed to local GLP-1R stimulation or the peripheral effects that improve atherosclerosis is yet to be elucidated [31, 32]; however, the anti-inflammatory properties of this drug class indisputably play a pivotal role.”
Background
Metadata
- Authors
- Rizvi, A. A., Patti, A. M., Giglio, R. V., Nikolic, D., Amato, A., Al-Busaidi, N., Al-Rasadi, K., Soresi, M., Banach, M., Montalto, G., & Rizzo, M.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-07-20
- Volume
- 15
- Issue
- 10
- Pages
- 1391-1397
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1700218887
- Cited by
- 52
- References
- 13
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. https://app.cochat.ai/papers/10.1517/14712598.2015.1067299
- The paper
- Rizvi, A. A., Patti, A. M., Giglio, R. V., Nikolic, D., Amato, A., Al-Busaidi, N., Al-Rasadi, K., Soresi, M., Banach, M., Montalto, G., & Rizzo, M. (2015). Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2015.1067299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.